January 23, 2026
Sanofi’s Amlitelimab Shows Mixed Phase 3 Results in Eczema Trials, Clouds Blockbuster Hopes but Advances to Regulatory Filings
Sanofi; amlitelimab; Phase 3; eczema; atopic dermatitis; COAST; SHORE; vIGA-AD; EASI-75
Novo Nordisk’s Wegovy Pill Launches Strongly Amid Analyst Caution
Wegovy pill; Novo Nordisk; FDA approval; oral GLP-1; obesity drug; Eli Lilly competition
Corxel Pharmaceuticals Raises $287M Series D1 to Advance Oral GLP-1 Obesity Drug CX11
Corxel Pharmaceuticals; Series D1; GLP-1; CX11; obesity drug; funding; Vincentage
Hua Medicine Advances Dorzagliatin Expansion Beyond China with Hong Kong NDA Acceptance
Hua Medicine; dorzagliatin; diabetes drug; China expansion; Hong Kong NDA; Southeast Asia; glucokinase activator
BioMarin Veterans Launch Mendra Biotech with $82M for AI-Driven Rare Disease Drugs
Mendra; BioMarin; rare disease; biotech startup; $82M; Series A; AI drug development
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
MBX Biosciences; Laurie Stelzer; Board Appointment; Audit Committee; Independent Director
Thousands Could Benefit from New Take-at-Home Treatment for Advanced Prostate Cancer
prostate cancer; talazoparib; Talzenna; NICE; NHS; enzalutamide
Insilico Medicine to Present Three Abstracts on ISM5411 at 2026 Crohn’s & Colitis Congress
Insilico Medicine; ISM5411; Crohn’s & Colitis Congress; Inflammatory Bowel Disease; PHD1/2 Inhibitor; Phase 1 Data